Floatz logo

HYDRAZINECARBOXIMIDAMIDE, 2,2'-(1-METHYL-1,2-ETHANEDIYLIDENE)BIS-, (E,E)-

Acute Myeloid Leukemia

French Innovative Leukemia OrganisationSmall moleculePhase 3Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
59/ 100

Competitive context

374 Active assets in the Acute Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
Idarubicine
Institute of Hematology & Blood Diseases Hospital, China
Phase 4BB
ETOPOSIDE
Memorial Sloan Kettering Cancer Center
Phase 4BB
Busulphan
Sawa Ito, MD
Phase 4BB
Azacitidine
European Organisation for Research and Treatment of Cancer - EORTC
Phase 4BB
CYCLOSPORIN A
City of Hope Medical Center
Phase 4BB

View all 50 →

Same molecule, other indications

HYDRAZINECARBOXIMIDAMIDE, 2,2'-(1-METHYL-1,2-ETHANEDIYLIDENE)BIS-, (E,E)- is also rated in:

HIV infectious diseaseDormant
B
Indicative ·
57 / 100
View asset →
non-Hodgkin lymphomaDormant
CCC
Indicative ·
54 / 100
View asset →
lymphomaDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →